North Dakota State Investment Board Takes Position in Stryker Corporation $SYK

North Dakota State Investment Board acquired a new stake in shares of Stryker Corporation (NYSE:SYK) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 11,804 shares of the medical technology company’s stock, valued at approximately $4,149,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. United Financial Planning Group LLC bought a new position in shares of Stryker during the third quarter valued at approximately $27,000. Strive Asset Management LLC bought a new position in shares of Stryker during the third quarter valued at approximately $30,000. CGC Financial Services LLC bought a new position in shares of Stryker during the fourth quarter valued at approximately $29,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker during the third quarter valued at approximately $34,000. Finally, Copia Wealth Management boosted its stake in shares of Stryker by 181.6% during the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Down 0.0%

NYSE:SYK opened at $306.74 on Monday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The firm has a fifty day simple moving average of $329.68 and a 200-day simple moving average of $351.50. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $117.59 billion, a P/E ratio of 35.50, a PEG ratio of 1.93 and a beta of 0.80.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period last year, the business earned $2.84 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Activity

In related news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on SYK shares. JPMorgan Chase & Co. lowered their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Barclays lowered their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. TD Cowen downgraded shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price for the company. in a research note on Monday, January 26th. Wells Fargo & Company lowered their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Truist Financial restated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.